Today: 7 February 2026
Subscribe
Browse Category

NYSE:WELL News 4 January 2026 - 19 January 2026

REITs face a Tuesday test after MLK shutdown as XLRE, VNQ eye rates and policy

REITs face a Tuesday test after MLK shutdown as XLRE, VNQ eye rates and policy

U.S. real estate ETFs rose Friday, with XLRE up 1.2% to $42.21 and VNQ closing at $92.62. Markets are closed Monday for the Martin Luther King Jr. holiday. Prologis reports earnings Wednesday, coinciding with new housing data and a Trump policy speech in Davos. Investors are watching for signals ahead of the Federal Reserve’s late-January meeting.
19 January 2026
·······
MPW stock ends higher to start 2026 as investors watch rates and Medical Properties Trust’s dividend

MPW stock ends higher to start 2026 as investors watch rates and Medical Properties Trust’s dividend

NEW YORK, January 3, 2026, 17:44 ET — Market closed Medical Properties Trust, Inc. (NYSE: MPW) shares climbed 1.6% on Friday to close at $5.08. U.S. markets are closed on Saturday. Nasdaq The move matters because MPW is a high-yield real estate investment trust, or REIT — a structure that typically returns a large share of taxable income to investors as dividends. That makes the stock sensitive to shifts in interest-rate expectations and the price of capital. Medical Properties Trust At $5.08, MPW is still about 20% below its 52-week high of $6.34, but well above its $3.51 low, keeping
4 January 2026
·······

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop